Dogwood Therapeutics, Inc.
$ 1.79
-4.79%
14 Apr - close price
- Market Cap 62,596,000 USD
- Current Price $ 1.79
- High / Low $ 1.97 / 1.77
- Stock P/E N/A
- Book Value 2.52
- EPS -7.13
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.19 %
- ROE -0.49 %
- 52 Week High 9.50
- 52 Week Low 1.77
About
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company is headquartered in Alpharetta, Georgia.
Analyst Target Price
$14.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-12-31 | 2025-11-07 | 2025-08-13 | 2025-05-07 | 2025-03-13 | 2024-11-11 | 2024-08-08 | 2024-05-09 | 2024-02-29 | 2023-11-13 | 2023-08-10 | 2023-05-11 |
| Reported EPS | -0.26 | -8.2 | -9.51 | -8.4504 | -6.29 | -2.05 | -0.05 | -0.07 | -0.06 | -0.06 | -0.08 | -0.08 |
| Estimated EPS | -0.86 | -0.05 | -0.05 | -0.765 | -0.0567 | -0.06 | -0.0633 | -0.05 | -0.06 | -0.09 | -0.05 | -0.16 |
| Surprise | 0.6 | -8.15 | -9.46 | -7.6854 | -6.2333 | -1.99 | 0.0133 | -0.02 | 0 | 0.03 | -0.03 | 0.08 |
| Surprise Percentage | 69.7674% | -16300% | -18920% | -1004.6275% | -10993.4744% | -3316.6667% | 21.0111% | -40% | 0% | 33.3333% | -60% | 50% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.22 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DWTX
2026-03-29 13:39:58
Virios Therapeutics (NASDAQ: VIRI) is a clinical-stage biotechnology company focused on developing oral antiviral therapies for chronic conditions such as ME/CFS and Long COVID. Their lead candidate, IMC-1, targets persistent viral infections like HHV-6. The company aims to advance its pipeline through Phase 2 trials and partner for late-stage development, positioning itself in a niche market with significant unmet medical needs.
2026-03-29 11:10:01
Virios Therapeutics focuses on developing novel antiviral therapies for chronic conditions like ME/CFS and Long COVID, positioning itself as a high-risk, high-reward investment in the biotech sector. The company's lead candidate, IMC-1, is an oral antiviral in Phase 2 trials, targeting persistent viral infections and aiming to restore immune balance. While the market for post-viral syndromes presents significant opportunities, investors should be aware of inherent risks associated with clinical trial outcomes and funding needs.
2026-03-25 04:39:09
Virios Therapeutics (NASDAQ:VIRI) stock dropped 7.3% on Tuesday to $2.78 on very low trading volume, significantly below its moving averages. The clinical-stage biopharmaceutical company, which focuses on anti-fibrotic therapies and has a negative P/E ratio, faces small-cap and loss-making biotech risks. Analysts currently have a "Hold" rating on the stock, suggesting other investment opportunities might be more appealing.
2026-03-13 13:52:26
Virios Therapeutics, a clinical-stage biotech focused on antiviral therapies, has merged with Tonix Pharmaceuticals, integrating its assets into a diversified commercial-stage biopharma entity. This merger shifts the focus for legacy Virios shareholders from pure R&D to revenue-generating products like Tonix's FDA-approved TONMYA for fibromyalgia. The integration aims to address Virios's cash burn challenges and broaden Tonix's reach into CNS and antiviral treatments, offering a more diversified and de-risked pipeline for investors.
2026-02-25 18:51:12
This page provides comprehensive news and analysis for Dogwood Therapeutics (DWTX), a biopharmaceutical company focused on pain and neuropathy treatments. Key updates include the dosing of the first patient in a Phase 2b trial for Halneuron® for chemotherapy-induced neuropathic pain, recent financing through a direct offering, and the conversion of $19.5M in debt to equity, strengthening the company's balance sheet. The company also announced plans to commence patient dosing for Halneuron® in Q1 2025 and reported on a study showing IMC-2 treatment reduces Long-COVID related fatigue.
2026-02-06 11:59:29
Virios Therapeutics (NASDAQ:VIRI) shares increased 1.7% to $3.08 on Thursday, despite very light trading volume, which was 98% below its daily average. The clinical-stage biopharmaceutical company, focused on fibrotic diseases, has a market cap of $59.31 million and is trading below its 50-day and 200-day moving averages. Its lead drug candidate, VTI-1002, is in trials for hypertrophic scars and keloids, and the stock previously saw a significant jump after a fibromyalgia Phase 3 proposal.
